Package 69315-286-06

{"route": ["ORAL"], "spl_id": "f356d1ba-3572-4a79-9846-94ee2030f04b", "openfda": {"nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503"], "unii": ["0C50HW4FO1"], "rxcui": ["754761", "1052658"], "spl_set_id": ["48ffeac8-38e8-4007-903a-dbffce25d679"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "manufacturer_name": ["Leading Pharma, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET in 1 BOTTLE (69315-286-06)", "package_ndc": "69315-286-06", "marketing_start_date": "20220605"}], "brand_name": "ETRAVIRINE", "product_id": "69315-286_f356d1ba-3572-4a79-9846-94ee2030f04b", "dosage_form": "TABLET", "pharm_class": ["Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Non-Nucleoside Analog [EXT]", "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "69315-286", "generic_name": "ETRAVIRINE", "labeler_name": "Leading Pharma, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "ETRAVIRINE", "active_ingredients": [{"name": "ETRAVIRINE", "strength": "200 mg/1"}], "application_number": "ANDA215402", "marketing_category": "ANDA", "marketing_start_date": "20220605", "listing_expiration_date": "20261231"}